IsoRay, Inc.  

(Public, NYSEMKT:ISR)   Watch this stock  
Find more results for NYSEAMEX:ISR
Jul 11 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.44 - 3.77
Open     -
Vol / Avg. 0.00/2.71M
Mkt cap 149.04M
P/E     -
Div/yield     -
EPS -0.16
Shares 54.39M
Beta -0.43
Inst. own 4%

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -183.67% -85.22%
Operating margin -87.19% -89.88%
EBITD margin - -73.11%
Return on average assets -47.23% -52.97%
Return on average equity -53.74% -69.15%
Employees 36 -
CDP Score - -


Suite 106, 350 Hills St.
United States - Map
+1-509-3751202 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


IsoRay, Inc. (IsoRay) develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. IsoRay International LLC (International) is a wholly owned subsidiary of the Company. IsoRay obtained clearance from the Food and Drug Association for treatment for all solid tumor applications using Cesium-131. Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; breast cancer; liver cancer; brain cancer; colorectal cancer; gynecological cancer; esophageal cancer, and pancreatic cancer. The seed may be used in surface, interstitial and intracavity applications for tumors with known radio sensitivity. IsoRay has an existing distribution agreement with UralDial LLC (UralDial) that allows UralDial to distribute Proxcelan Cs-131 brachytherapy seeds in Russia. The Company, through UralDial, has regulatory approval to sell Cs-131 seeds in Russia.

Officers and directors

Dwight Babcock Chairman of the Board, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Brien Ragle Principal Financial and Accounting Officer, Controller
Age: 43
Bio & Compensation  - Reuters
Fredric Swindler Vice President - Regulatory and Quality Assurance
Age: 65
Bio & Compensation  - Reuters
William Cavanagh III Vice President - Research and Development
Age: 47
Bio & Compensation  - Reuters
Thomas C. LaVoy Independent Director
Age: 53
Bio & Compensation  - Reuters
Philip J. Vitale M.D. Independent Director
Age: 67
Bio & Compensation  - Reuters